KP
AXDX

Kiski Partners’s Accelerate Diagnostics AXDX Stock Holding History

Kiski Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$121K Buy
+564
New +$103K 0.46% 16

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kiski Partners's AXDX Position: Q4 2015 in Review

Kiski Partners opened a new position in Accelerate Diagnostics (AXDX) in Q4 2015: 564 shares worth $121K. The stake represents 0.46% of the portfolio and ranks #16 among its holdings.

97 funds tracked by Wall St. Rank hold AXDX as of Q4 2015.

  • Kiski Partners held 564 shares of Accelerate Diagnostics worth $121K as of Q4 2015.
  • Accelerate Diagnostics was a new Kiski Partners position in Q4 2015.
  • Accelerate Diagnostics made up 0.46% of Kiski Partners's portfolio in Q4 2015, its #16 holding.
  • 97 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2015.

Based on Kiski Partners's 13F filing for Q4 2015, filed 18 Feb 2016.